We leverage our proprietary kinase switch control inhibitor platform to develop of highly selective, potent small molecule drug candidates that directly inhibit activation of kinases implicated in the growth and spread of cancers.

  Pre-ClinicalPhase 1Phase 1b/2Phase 3Regulatory SubmissionApprovedCommercial Rights
ripretinib
Broad Spectrum Inhibitor of KIT & PDGFRα
GIST ≥4th Line (INVICTUS Study)
 
   flag1 flag2flagflagflagDeciphera Logo3
GIST 2nd Line (INTRIGUE Study)
 
     
DCC-3014
Selective Inhibitor of CSF1R
Tenosynovial Giant Cell Tumors
 
     Deciphera Logo
Rebastinib
Selective Inhibitor of TIE2
Solid Tumors in Combination with Paclitaxel
(includes breast, ovarian & endometrial cancers)
 
     Deciphera Logo
Solid Tumors in Combination with Carboplatin
(includes mesothelioma, ovarian & breast cancers)
 
 
     
DCC-3116
Selective Inhibitor of ULK
Autophagy Inhibitor Targeting RAS Mutant Cancers
 
     Deciphera Logo
Additional ProgramsUndisclosed 
 
     Deciphera Logo
Ripretinib3: Broad Spectrum Inhibitor of KIT & PDGFRα
Phase Commercial Rights
GIST ≥4th Line (INVICTUS Study)   Regulatory Submission1,2 Deciphera
Development and commercialization exclusive license with Zai Lab in Greater China.
GIST 2nd Line (INTRIGUE Study)   Phase 3 Deciphera
DCC-3014: Selective Inhibitor of CSF1R
Phase Commercial Rights
Tenosynovial Giant Cell Tumors   Phase 1 Deciphera
Rebastinib: Selective Inhibitor of TIE2
Phase Commercial Rights
Solid Tumors in Combination with Paclitaxel
(includes breast, ovarian & endometrial cancers)
 
Phase 1b/2 Deciphera
Solid Tumors in Combination with Carboplatin
(includes mesothelioma, ovarian & breast cancers)
 
Phase 1b/2 Deciphera
DCC-3116: Selective Inhibitor of ULK
Phase Commercial Rights
Autophagy Inhibitor Targeting RAS Mutant Cancers Pre-clinical Deciphera
Additional Programs
Phase Commercial Rights
Undisclosed   Pre-clinical Deciphera

Notes: CSF1R=colony stimulating factor 1 receptor; GIST=gastrointestinal stromal tumor; KIT=KIT proto-oncogene receptor tyrosine kinase; PDGFRα=platelet-derived growth factor receptor α; RAS=rat sarcoma gene; TIE2=TEK tyrosine kinase; ULK=unc-51-like kinase.
1) Submitted and received validation of a Marketing Application for QINLOCK in fourth-line GIST by European Medicines Agency; 2) China National Medical Products Administration has accepted a New Drug Application for ripretinib for a treatment of adult patients with fouth-line GIST; 3) Development and commercialization exclusive license with Zai Lab in Greater China

Pipeline graphic is not for promotional use.